Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
115 hedge funds and large institutions have $311M invested in Astria Therapeutics in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 36 reducing their positions, and 13 closing their positions.
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
5% more funds holding
Funds holding: 110 → 115 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.4% less ownership
Funds ownership: 103.75% → 103.35% (-0.4%)
6% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 36
40% less capital invested
Capital invested by funds: $523M → $311M (-$212M)
86% less call options, than puts
Call options by funds: $5K | Put options by funds: $36K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIS
FCPM III Services
Naarden,
Netherlands
|
+$6.65M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$3.85M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$3.07M |
| 4 |
Renaissance Technologies
New York
|
+$1.25M |
| 5 |
Jane Street
New York
|
+$579K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.21M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.12M |
| 3 |
Millennium Management
New York
|
-$2.03M |
| 4 |
SCM
Sio Capital Management
New York
|
-$1.33M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.16M |
ATXS Hedge Fund Activity: Q1 2025 in Review
115 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q1 2025, worth a combined $311M — down 40% from $523M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ATXS positions and 13 closed out — a net gain of 5 holders — while 34 added to existing stakes and 36 trimmed.
The largest buyer was FCPM III Services, adding an estimated $6.65M. The largest seller was Fidelity Investments, cutting an estimated $6.21M.
- 115 institutional investors held Astria Therapeutics (ATXS) as of Q1 2025, up from 110 in Q4 2024.
- Funds reported $311M of Astria Therapeutics stock for Q1 2025, down 40% quarter-over-quarter.
- 18 funds opened new Astria Therapeutics positions in Q1 2025 and 13 closed out, a net change of +5 holders.
- The largest Astria Therapeutics buyer in Q1 2025 was FCPM III Services, an estimated $6.65M added.
- The largest Astria Therapeutics seller in Q1 2025 was Fidelity Investments, an estimated $6.21M sold.
Based on aggregated 13F filings for Q1 2025.